Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir

AIDS Research and Human Retroviruses

Volumn 31, Issue 1, 2015, Pages 115-126

  Moniuszko, Marcin ^a   Liyanage, Namal P M ^b   Doster, Melvin N ^b   Parks, Robyn Washington ^b   Grubczak, Kamil ^a   Lipinska, Danuta ^a   Mckinnon, Katherine ^b   Brown, Charles ^c   Hirsch, Vanessa ^c   Vaccari, Monica ^b   Gordon, Shari ^b   Pegu, Poonam ^b   Fenizia, Claudio ^b   Flisiak, Robert ^a   Grzeszczuk, Anna ^a   Dabrowska, Milena ^a   Robert Guroff, Marjorie ^b   Silvestri, Guido ^d   Stevenson, Mario ^e   Mccune, Joseph ^f   Franchini, Genoveffa ^b   more..

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; GLUCOCORTICOID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FC RECEPTOR; VIRUS DNA;

ARTICLE; BLOOD; CERCOCEBUS ATYS; CORTICOSTEROID THERAPY; DISEASE CARRIER; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VIVO STUDY; INTESTINE; LYMPH NODE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN; ANIMAL; CD4 LYMPHOCYTE COUNT; DRUG EFFECTS; FEMALE; GASTROINTESTINAL TRACT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; IMMUNOLOGY; MACROPHAGE; MALE; METABOLISM; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD14; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CERCOCEBUS ATYS; DNA, VIRAL; FEMALE; GASTROINTESTINAL TRACT; GLUCOCORTICOIDS; HIV INFECTIONS; HUMANS; LYMPH NODES; MACACA MULATTA; MACROPHAGES; MALE; MONOCYTES; RECEPTORS, IGG; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN; VIRAL LOAD;

EID: 84929948140     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0220     Document Type: Article

References (44)

1. Gartner S, Markovits P, Markovitz DM, et al.: The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986;233:215-219
2. Ho DD, Rota TR, and Hirsch MS: Infection of monocyte/ macrophages by human T lymphotropic virus type III. J Clin Invest 1986;77:1712-1715
3. Pauza CD, Galindo J, and Richman DD: Human immunodeficiency virus infection of monoblastoid cells: Cellular differentiation determines the pattern of virus replication. J Virol 1988;62:3558-3564
4. Shi C and Pamer EG: Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011;11:762-774
5. Wong KL, Tai JJ, Wong WC, et al.: Gene expression profiling reveals the defining features of the classical, intermediate,and nonclassical human monocyte subsets. Blood 2011;118:e16-e31
6. Zawada AM, Rogacev KS, Rotter B, et al.: SuperSAGE evidence for CD14+ + CD16 + monocytes as a third monocyte subset. Blood 2011;118:e50-e61
7. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al.: Nomenclature of monocytes and dendritic cells in blood. Blood 2010;116:e74-e80
8. van Furth FR and Cohn ZA: The origin and kinetics of mononuclear phagocytes. J Exp Med 1968;128:415-435
9. Weiner LM, Li W, Holmes M, et al.: Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: Toxicity, monocytosis, and clinical effects. Cancer Res 1994;54:4084-4090
10. Ziegler-Heitbrock HW, Fingerle G, Strobel M, et al.: The novel subset of CD14 + /CD16 + blood monocytes exhibits features of tissue macrophages. Eur J Immunol 1993;23: 2053-2058
11. Kim WK, Sun Y, Do H, et al.: Monocyte heterogeneity underlying phenotypic changes in monocytes according to SIV disease stage. J Leukoc Biol 2010;87:557-567
12. Espinoza-Jimenez A, Peon AN, and Terrazas LI: Alternatively activated macrophages in types 1 and 2 diabetes. Mediators Inflamm 2012;2012:815953
13. Hearps AC, Maisa A, Cheng WJ, et al.: HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012;26:843-853
14. Hearps AC, Martin GE, Angelovich TA, et al.: Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell 2012;11:867-875
15. Hovden H, Frederiksen JL, and Pedersen SW: Immune system alterations in amyotrophic lateral sclerosis. Acta Neurol Scand 2013;128:287-296
16. Madjid M and Fatemi O: Components of the complete blood count as risk predictors for coronary heart disease: In-depth review and update. Tex Heart Inst J 2013;40:17-29
17. Terry RL, Getts DR, Deffrasnes C, et al.: Inflammatory monocytes and the pathogenesis of viral encephalitis. J Neuroinflam 2012;9:270
18. Woollard KJ: Immunological aspects of atherosclerosis. Clin Sci (Lond) 2013;125:221-235
19. Ziegler-Heitbrock L: The CD14 + CD16 + blood monocytes: Their role in infection and inflammation. J Leukoc Biol 2007;81:584-592
20. Ellery PJ, Tippett E, Chiu YL, et al.: The CD16 + monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 2007;178:6581-6589
21. Han J, Wang B, Han N, et al.: CD14(high)CD16( + ) rather than CD14(low)CD16( + ) monocytes correlate with disease progression in chronic HIV-infected patients. J Acquir Immune Defic Syndr 2009;52:553-559
22. Jaworowski A, Kamwendo DD, Ellery P, et al.: CD16 +monocyte subset preferentially harbors HIV-1 and is expanded in pregnant Malawian women with Plasmodium falciparum malaria and HIV-1 infection. J Infect Dis 2007;196:38-42
23. Ancuta P, Autissier P, Wurcel A, et al.: CD16 + monocytederived macrophages activate resting T cells for HIV infection by producing CCR3 and CCR4 ligands. J Immunol 2006;176:5760-5771
24. Lambotte, O, Taoufik Y, de Goer MG, et al.: Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;23:114-119
25. Sonza S, Mutimer HP, Oelrichs R, et al.: Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001;15:17-22
26. Zhu T, Muthui D, Holte S, et al.: Evidence for human immunodeficiency virus type 1 replication in vivo in CD14( + ) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002;76:707-716
27. Fingerle-Rowson G, Angstwurm M, Andreesen R, et al.: Selective depletion of CD14 + CD16 + monocytes by glucocorticoid therapy. Clin Exp Immunol 1998;112:501-506
28. Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, et al.: Enhanced frequencies of CD14+ + CD16 + , but not CD14 + CD16 + , peripheral blood monocytes in severe asthmatic patients. Clin Immunol 2009;130:338-346
29. Dayyani F, Belge KU, Frankenberger M, et al.: Mechanism of glucocorticoid-induced depletion of human CD14 +CD16 + monocytes. J Leukoc Biol 2003;74:33-39
30. Moniuszko M, Kowal K, Rusak M, et al.: Monocyte CD163 and CD36 expression in human whole blood and isolated mononuclear cell samples: Influence of different anticoagulants. Clin Vaccine Immunol 2006;13:704-707
31. Romano JW, Williams KG, Shurtliff RN, et al.: 1997. NASBA technology: Isothermal RNA amplification in qualitative and quantitative diagnostics. Immunol Invest 1997;26:15-28
32. Chung HK, Unangst T, Treece J, et al.: Development of real-time PCR assays for quantitation of simian beta retrovirus serotype-1, -2, -3, and -5 viral DNA in Asian monkeys. J Virol Methods 2008;152:91-97
33. Hofmann-Lehmann R, Swenerton RK, Liska V, et al.: Sensitive and robust one-tube real-time reverse transcriptasepolymerase chain reaction to quantify SIV RNA load: Comparison of one- versus two-enzyme systems. AIDS Res Hum Retroviruses 2000;16:1247-1257
34. Lee EM, Chung HK, Livesay J, et al.: Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simianhuman immunodeficiency viruses. J Virol Methods 2010; 163:287-294
35. Paiardini M, Cervasi B, Reyes-Aviles E, et al.: Low levels of SIV infection in sooty mangabey central memory CD T cells are associated with limited CCR5 expression. Nat Med 2011;17:830-836
36. Pandrea I, Onanga R, Souquiere S, et al.: Paucity of CD4 +CCR5 + T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding. J Virol 2008;82:5501-5509
37. Chrousos GP, Renquist D, Brandon D, et al.: Glucocorticoid hormone resistance during primate evolution: Receptor-mediated mechanisms. Proc Natl Acad Sci USA 1982;79:2036-2040
38. Crum NF, Riffenburgh RH, Wegner S, et al.: Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006;41:194-200
39. Chun TW, Engel D, Mizell SW, et al.: Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999;5:651-655
40. Davey RT Jr, Bhat N, Yoder C, et al.: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999;96:15109-15114
41. Dutertre CA, Amraoui S, DeRosa A, et al.: Pivotal role of M-DC8( + ) monocytes from viremic HIV-infected patients in TNFalpha overproduction in response to microbial products. Blood 2012;120:2259-2268
42. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371
43. Williams DW, Eugenin EA, Calderon TM, et al.: Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol 2012;91:401-415
44. Hunt PW, Shulman NS, Hayes TL, et al.: The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4 + T-cell recovery: A randomized trial. Blood 2013;121:4635-4646